Acceleron Pharma, Inc.

Acceleron Pharma, Inc. is an American clinical-stage biopharmaceutical company. Based in Cambridge, Massachusetts, Acceleron Pharma, Inc. is focused on developing medicines that target multiple ligands (proteins) in the TGF-beta superfamily, which are critical in the development of serious diseases. Acceleron Pharma, Inc., a publicly traded company, has three drugs in clinical trials and recently announced the U.S. Food and Drug Administration (FDA) approved REBLOZYL.

Acceleron Pharma, Inc. is an American clinical-stage biopharmaceutical company. Based in Cambridge, Massachusetts, Acceleron Pharma, Inc. is focused on developing medicines that target multiple ligands (proteins) in the TGF-beta superfamily, which are critical in the development of serious diseases. Acceleron Pharma, Inc., a publicly traded company, has three drugs in clinical trials and recently announced the U.S. Food and Drug Administration (FDA) approved REBLOZYL.